14 years ago

PolyTherics Secures £2.15 Million to Advance Protein and Peptide Drug Solutions

  • PolyTherics, a London-based company specializing in improving protein and peptide based drugs, has secured £2.15 million in funding

  • The round was led by existing investor Imperial Innovations Group plc, with participation from new backer ProVen Health VCT Plc

  • and current shareholder YFM Equity Partners

  • The investment will be used to apply PolyTherics' technologies to an expanding range of proteins and peptides and pursue new applications, such as providing a more stable linker for antibody and protein drug conjugates.

      • ProblemHealthcare

      "Drug companies need to improve the duration of action of protein and peptide based drugs so that they are more effective and reduce side effects."

      Solution

      "PolyTherics has developed technologies that slow the elimination of drugs from the body by attaching the polymer Polyethylene Glycol (PEG) to therapeutic peptides and proteins. This process, known as PEGylation, allows for drugs to be dosed less frequently, which can decrease side effects and improve patient compliance."

      Covered on